Head-to-head evidence
abrocitinib vs upadacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1 · full Atopic Dermatitis pipeline
abrocitinib · Cibinqo
Marketed by Pfizer
NCT03349060 · Phase 3 · completed
A randomized, quadruple-blind, placebo-controlled phase 3 trial enrolling 387 participants with moderate-to-severe atopic dermatitis. The co-primary endpoints (IGA response and EASI-75 at week 12) were both statistically significant for the 100 mg and 200 mg doses versus placebo, with large absolute differences (e.g. 43.8% vs 7.9% for IGA). The adequate sample size, blinded design, and positive hard clinical endpoints justify the strong evidence grade.
Next expected readout: March 2027 · NCT07242638 (registry estimate)
upadacitinib · Rinvoq
Marketed by AbbVie
NCT03607422 · Phase 3 · completed
Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).
Next expected readout: January 2027 · NCT06701331 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: abrocitinib's landscape · upadacitinib's landscape